Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Clover Health Investments, Corp.NASDAQ: CLOV
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $28.57M, compared with -$10.18M a year earlier. Trailing-twelve-month EBITDA was -$16.46M.
Context
- EBITDA amounted to 4.4% of revenue in FY2025, up 1.1 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $41.46M (+149.4%) for the fiscal year ending Dec 2026, a step up from the -86.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $28.57M+2.6% QoQ
- Last fiscal yearDec 2025
- -$83.86M-86.6% YoY
- LTMJun 2026
- -$16.46M+60.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +380.5% | +90.8% | -289.7 pp |
| 1 year | -86.6% | +149.4% | +236.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (83.86M) USD
- Year-over-year change
- -86.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83.86M) | -86.6% |
| FY2024 | 2024-12-31 | (44.94M) | +78.4% |
| FY2023 | 2023-12-31 | (207.63M) | +17.6% |
| FY2022 | 2022-12-31 | (252.03M) | +55.8% |
| FY2021 | 2021-12-31 | (569.6M) | — |
EBITDA vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 EBITDA of -$16.46M is the 6th highest of the 7 companies compared; the peer median is $1.94B.
- Its year-over-year change of +60.0% is the 3rd highest of 7, against a peer median of +2.9%.
- EBITDA amounts to 0.7% of revenue for CLOV, versus a peer median of 2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.41B | -5.4% | -7.2% | 3.2% | |
| LTM Sep 2026 | $12.53B | +1.2% | +0.7% | 4.4% | |
| LTM Sep 2026 | $3.24B | +4.5% | -15.4% | 2.1% | |
| LTM Jun 2026 | $633.7M | +751.9% | — | 4.1% | |
| LTM Mar 2026 | $66.42M | +265.7% | — | 1.6% | |
| LTM Jun 2026 | -$16.46M | +60.0% | — | 0.7% | |
| LTM Jun 2026 | -$2.73B | -158.1% | — | 1.4% | |
| Peer median (excluding CLOV) | $1.94B | +2.9% | -7.2% | 2.7% | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.47B | 1.1B | 1.26B | 1.37B | 1.92B |
| Cost of Revenue | 1.55B | 993.07M | 1B | 1.01B | 1.57B |
| Gross Profit | (79.18M) | 103.48M | 255.95M | 364.8M | 355.88M |
| Gross Margin | -5.4% | 9.4% | 20.3% | 26.6% | 18.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 445.75M | 482.4M | 440.25M | 408.93M | 176.32M |
| Operating Expenses | 557.81M | 390.14M | 461.28M | 410.55M | 441.43M |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| EBITDA | (569.6M) | (252.03M) | (207.63M) | (44.94M) | (83.86M) |
| EBITDA Margin | -38.7% | -23.0% | -16.5% | -3.3% | -4.4% |
| Operating Income | (636.99M) | (286.66M) | (205.33M) | (45.75M) | (85.53M) |
| Operating Margin | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 16.91M | 1.36M | 7K | 0 | 0 |
| Other Income / Expenses | 49.24M | 32.08M | (4.82M) | (517K) | (20K) |
| Income Before Tax | (587.76M) | (254.58M) | (210.15M) | (46.27M) | (85.55M) |
| Pre-Tax Margin | -39.9% | -23.2% | -16.7% | -3.4% | -4.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Net Margin | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% |
| EPS (Basic) | (1.25) | (0.71) | (0.45) | (0.09) | (0.17) |
| EPS (Diluted) | (1.25) | (0.71) | (0.45) | (0.09) | (0.17) |
| Weighted Avg Shares | 470.85M | 476.24M | 482.18M | 490.02M | 517.24M |
| Weighted Avg Shares (Diluted) | 470.85M | 476.24M | 482.18M | 490.02M | 517.24M |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.